Using state-of-the-art, high-throughput mass spectrometry technologies, Sapient’s metabolomics, lipidomics, and proteomics approaches enable biopharma sponsors to go beyond the genome with multi-omics biomarker discovery to accelerate precision drug development.
Our large-scale, multi-omics profiling focuses on non-genetic biomarkers – capturing thousands of metabolites, lipids, and proteins per biosample, across thousands of samples at a time – to give you an unprecedented view into the dynamic factors that modulate health, disease, and drug response across individuals.
Through our integrated multi-omics biomarker discovery services, including data generation and analysis and biomarker validation and translation, we generate greater biological insight from every sample and enable you to better align disease, patients, and therapies.
Download the fact sheet to learn how we enable nontargeted multi-omics measurements to capture dynamic biomarkers at scale in cellular, preclinical, and human biosamples – and how with more measures, you gain more actionable insight and more confidence to de-risk and optimize development at any phase.